EurekAlert! Cancer Research

News Releases

Updates every hour. Last Updated: 26-Jun-2026 11:17 ET (26-Jun-2026 15:17 GMT/UTC)

14-Mar-2026

Prostate cancer screening as good as breast cancer screening, say researchers

European Association of Urology
Reports and Proceedings

Prostate cancer screening compares favourably to screening for breast cancer in identifying significant cancers, reducing mortality and avoiding unnecessary harms, says new research.

Meeting: EAU26 European Association of Urology Congress

13-Mar-2026

The power of photonics

University of Illinois Grainger College of Engineering
Peer-Reviewed Publication

Timing is critical in diagnosing diseases such as cancer. Researchers within The Grainger College of Engineering at the University of Illinois Urbana-Champaign used a historically underappreciated tiny powerhouse to detect diseases sooner.

Journal: Chemical Reviews

13-Mar-2026

Bursting cancer-seeking microbubbles to deliver deadly drugs

Duke University
Peer-Reviewed Publication

Engineers at Duke University have demonstrated a technique that uses microbubbles and ultrasound to help relatively large cancer drugs enter tumor cells and cause them to self-destruct.

Journal: Proceedings of the National Academy of Sciences

13-Mar-2026

A new method produces CAR-T cells to keep fighting disease longer

Albert Einstein College of Medicine
Peer-Reviewed Publication

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells that dramatically prolongs their effectiveness after being infused into patients to fight cancer and HIV, addressing a major limitation of current treatments. Their findings, published today in Science Advances, describe a manufacturing approach that, compared to the existing process, generates longer-lasting immune cells that provide more sustained control of human blood cancers and suppression of HIV-infection in mouse models.

Journal: Science Advances

13-Mar-2026

Rewriting cancer immunotherapy: Why CD4+ T cells matter more than we thought

China Anti-Cancer Association
Peer-Reviewed Publication

CD4⁺ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and immune resistance.

Journal: Cancer Biology & Medicine

13-Mar-2026

Can exercise help chemo brain? New research adds promising results

University of Rochester Medical Center
Peer-Reviewed Publication

For patients taking chemotherapy on two-week cycles, exercise "prescriptions" allowed them to stay mentally sharp and maintain daily steps.

Journal: Journal of the National Comprehensive Cancer Network

13-Mar-2026

FDA-approved cancer drug fedratinib reshapes how cell organelles communicate, providing new therapeutic avenues

Michigan Medicine - University of Michigan
Peer-Reviewed Publication

In a new study, University of Michigan researchers found that the FDA-approved drug fedratinib can lead to ERMCS formation, providing a potential therapeutic avenue.

Journal: Molecular Cell

13-Mar-2026

How vitamin B2 could pave the way to new cancer therapies

University of Würzburg
Peer-Reviewed Publication

A lack of vitamin B2 makes tumour cells more susceptible to a unique form of cell death. This was discovered by researchers at the Rudolf Virchow Centre at the University of Würzburg.

Journal: Nature Cell Biology

13-Mar-2026

Researchers break decades-old bottleneck in chemotherapy drug manufacturing

University of Turku
Peer-Reviewed Publication

An international team of researchers has achieved a breakthrough in the production of doxorubicin, a vital chemotherapy agent. The study identifies and resolves molecular "bottlenecks" that have limited the natural production of this drug for over 50 years.

Journal: Nature Communications

13-Mar-2026

Senolytic therapy of PDAC

Kanazawa University
Peer-Reviewed Publication

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 inhibition offers an indirect strategy to counter KRAS-driven malignancy without direct KRAS targeting.

Journal: Cell Death and Differentiation